310 related articles for article (PubMed ID: 26225745)
1. Targeted disruption of fibrinogen like protein-1 accelerates hepatocellular carcinoma development.
Nayeb-Hashemi H; Desai A; Demchev V; Bronson RT; Hornick JL; Cohen DE; Ukomadu C
Biochem Biophys Res Commun; 2015 Sep; 465(2):167-73. PubMed ID: 26225745
[TBL] [Abstract][Full Text] [Related]
2. The chemokine receptor CCR10 promotes inflammation-driven hepatocarcinogenesis via PI3K/Akt pathway activation.
Wu Q; Chen JX; Chen Y; Cai LL; Wang XZ; Guo WH; Zheng JF
Cell Death Dis; 2018 Feb; 9(2):232. PubMed ID: 29445190
[TBL] [Abstract][Full Text] [Related]
3. Role of insulin receptor substrates in the progression of hepatocellular carcinoma.
Sakurai Y; Kubota N; Takamoto I; Obata A; Iwamoto M; Hayashi T; Aihara M; Kubota T; Nishihara H; Kadowaki T
Sci Rep; 2017 Jul; 7(1):5387. PubMed ID: 28710407
[TBL] [Abstract][Full Text] [Related]
4. Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice.
Hu J; Che L; Li L; Pilo MG; Cigliano A; Ribback S; Li X; Latte G; Mela M; Evert M; Dombrowski F; Zheng G; Chen X; Calvisi DF
Sci Rep; 2016 Feb; 6():20484. PubMed ID: 26857837
[TBL] [Abstract][Full Text] [Related]
5. mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in Mice.
Chen X; Wang Y; Tao J; Shi Y; Gai X; Huang F; Ma Q; Zhou Z; Chen H; Zhang H; Liu Z; Sun Q; Peng H; Chen R; Jing Y; Yang H; Mao Y; Zhang H
Gastroenterology; 2015 Sep; 149(3):741-52.e14. PubMed ID: 25980751
[TBL] [Abstract][Full Text] [Related]
6. Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo.
Shao H; Gao C; Tang H; Zhang H; Roberts LR; Hylander BL; Repasky EA; Ma WW; Qiu J; Adjei AA; Dy GK; Yu C
J Hepatol; 2012 Jan; 56(1):176-83. PubMed ID: 21835141
[TBL] [Abstract][Full Text] [Related]
7. Liver haploinsufficiency of RuvBL1 causes hepatic insulin resistance and enhances hepatocellular carcinoma progression.
Mello T; Materozzi M; Zanieri F; Simeone I; Ceni E; Bereshchenko O; Polvani S; Tarocchi M; Marroncini G; Nerlov C; Guasti D; Bani D; Pinzani M; Galli A
Int J Cancer; 2020 Jun; 146(12):3410-3422. PubMed ID: 31721195
[TBL] [Abstract][Full Text] [Related]
8. Fibrinogen-Like Protein 1 Modulates Sorafenib Resistance in Human Hepatocellular Carcinoma Cells.
Son Y; Shin NR; Kim SH; Park SC; Lee HJ
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069373
[TBL] [Abstract][Full Text] [Related]
9. The correlation of fibrinogen-like protein-1 expression with the progression and prognosis of hepatocellular carcinoma.
Hua N; Chen A; Yang C; Dong H; He X; Ru G; Tong X; Zhou F; Wang S
Mol Biol Rep; 2022 Aug; 49(8):7911-7919. PubMed ID: 35776395
[TBL] [Abstract][Full Text] [Related]
10. [EEF1A2 inhibits the p53 function in hepatocellular carcinoma via PI3K/AKT/mTOR-dependent stabilization of MDM4].
Longerich T
Pathologe; 2014 Nov; 35 Suppl 2():177-84. PubMed ID: 25394965
[TBL] [Abstract][Full Text] [Related]
11. Oncogene-dependent addiction to carbohydrate-responsive element binding protein in hepatocellular carcinoma.
Ribback S; Che L; Pilo MG; Cigliano A; Latte G; Pes GM; Porcu A; Pascale RM; Li L; Qiao Y; Dombrowski F; Chen X; Calvisi DF
Cell Cycle; 2018; 17(12):1496-1512. PubMed ID: 29965794
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-6-stimulated progranulin expression contributes to the malignancy of hepatocellular carcinoma cells by activating mTOR signaling.
Liu F; Zhang W; Yang F; Feng T; Zhou M; Yu Y; Yu X; Zhao W; Yi F; Tang W; Lu Y
Sci Rep; 2016 Feb; 6():21260. PubMed ID: 26879559
[TBL] [Abstract][Full Text] [Related]
13. TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms.
Esparza-Baquer A; Labiano I; Sharif O; Agirre-Lizaso A; Oakley F; Rodrigues PM; Zhuravleva E; O'Rourke CJ; Hijona E; Jimenez-Agüero R; Riaño I; Landa A; La Casta A; Zaki MYW; Munoz-Garrido P; Azkargorta M; Elortza F; Vogel A; Schabbauer G; Aspichueta P; Andersen JB; Knapp S; Mann DA; Bujanda L; Banales JM; Perugorria MJ
Gut; 2021 Jul; 70(7):1345-1361. PubMed ID: 32907830
[TBL] [Abstract][Full Text] [Related]
14. Intravenous miR-144 inhibits tumor growth in diethylnitrosamine-induced hepatocellular carcinoma in mice.
He Q; Wang F; Honda T; Lindquist DM; Dillman JR; Timchenko NA; Redington AN
Tumour Biol; 2017 Oct; 39(10):1010428317737729. PubMed ID: 29072132
[TBL] [Abstract][Full Text] [Related]
15. Activation of SRY accounts for male-specific hepatocarcinogenesis: Implication in gender disparity of hepatocellular carcinoma.
Liu C; Ren YF; Dong J; Ke MY; Ma F; Monga SPS; Wu R; Lv Y; Zhang XF
Cancer Lett; 2017 Dec; 410():20-31. PubMed ID: 28942012
[TBL] [Abstract][Full Text] [Related]
16. The Role of Autophagy in Hepatocellular Carcinoma.
Lee YJ; Jang BK
Int J Mol Sci; 2015 Nov; 16(11):26629-43. PubMed ID: 26561802
[TBL] [Abstract][Full Text] [Related]
17. V-AKT murine thymoma viral oncogene homolog/mammalian target of rapamycin activation induces a module of metabolic changes contributing to growth in insulin-induced hepatocarcinogenesis.
Evert M; Calvisi DF; Evert K; De Murtas V; Gasparetti G; Mattu S; Destefanis G; Ladu S; Zimmermann A; Delogu S; Thiel S; Thiele A; Ribback S; Dombrowski F
Hepatology; 2012 May; 55(5):1473-84. PubMed ID: 22271091
[TBL] [Abstract][Full Text] [Related]
18. β-Arrestin1 enhances hepatocellular carcinogenesis through inflammation-mediated Akt signalling.
Yang Y; Guo Y; Tan S; Ke B; Tao J; Liu H; Jiang J; Chen J; Chen G; Wu B
Nat Commun; 2015 Jun; 6():7369. PubMed ID: 26077142
[TBL] [Abstract][Full Text] [Related]
19. Defective DNA strand break repair causes chromosomal instability and accelerates liver carcinogenesis in mice.
Teoh NC; Dan YY; Swisshelm K; Lehman S; Wright JH; Haque J; Gu Y; Fausto N
Hepatology; 2008 Jun; 47(6):2078-88. PubMed ID: 18506893
[TBL] [Abstract][Full Text] [Related]
20. Induction of p53 renders ATM-deficient mice refractory to hepatocarcinogenesis.
Teoh N; Pyakurel P; Dan YY; Swisshelm K; Hou J; Mitchell C; Fausto N; Gu Y; Farrell G
Gastroenterology; 2010 Mar; 138(3):1155-65.e1-2. PubMed ID: 19919837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
